Relapses among leprosy patients treated with multidrug therapy: experience in the leprosy control program of the All Africa Leprosy and Rehabilitation Training Center (ALERT) in Ethiopia; practical difficulties with diagnosing relapses; operational procedures and criteria for diagnosing relapses
- PMID: 1474281
Relapses among leprosy patients treated with multidrug therapy: experience in the leprosy control program of the All Africa Leprosy and Rehabilitation Training Center (ALERT) in Ethiopia; practical difficulties with diagnosing relapses; operational procedures and criteria for diagnosing relapses
Abstract
Multidrug therapy (MDT), according to the recommendations of a WHO Study Group of 1982, was introduced in the leprosy control program of the All African Leprosy and Rehabilitation Training Center (ALERT), Ethiopia, in January 1983. Paucibacillary (PB) patients are treated with 6 months of MDT. Multibacillary (MB) patients are treated with at least 2 years of MDT and until skin-smear negativity. An analysis was made of the relapses which had been diagnosed among self-reporting patients in four rural districts and Addis Ababa. Among 3065 PB patients, 34 relapses (1.1%) were diagnosed during an average period of 6.1 years after stopping MDT (range 2 1/2 to 7 1/2 years). Among 2379 MB patients, 24 relapses (1.0%) were diagnosed during an average period of 4.7 years after stopping MDT (range 2 1/2 to 6 years). The estimated relapse rate per 1000 patient-years after release from MDT was 2.1 for PB patients and 2.4 for MB patients. From the analysis of the clinical, bacteriological, and histopathological findings, it was concluded that there was strong positive evidence for the diagnosis for 16 of the 34 relapses in the PB patients and for 0 of the 24 relapses in the MB patients. The main cause for overdiagnosis of MB relapses was that too much reliance had been put on skin-smear results, without a careful comparison of the results with those from before, during, and at completion of MDT; the diagnosis was based on the finding of positive smears in one set of smears only; insufficient attention was given to finding solid-staining bacilli; and findings in biopsies, if these were examined, did not confirm the diagnosis. The main cause of overdiagnosis of PB relapses was that too much reliance was put on histological findings, while these are often inconclusive for differentiating between a relapse and late reversal reaction. Recommendations are made on how to limit overdiagnosis of relapses. Operational procedures and criteria for making the diagnosis under conditions where facilities for back-up histological and mouse foot pad investigations are not available are proposed.
Similar articles
-
Relapses in leprosy patients after release from dapsone monotherapy; experience in the leprosy control program of the all Africa Leprosy and Rehabilitation Training Center (ALERT) in Ethiopia.Int J Lepr Other Mycobact Dis. 1992 Jun;60(2):161-72. Int J Lepr Other Mycobact Dis. 1992. PMID: 1522358
-
Experience with WHO-recommended multidrug therapy (MDT) for multibacillary (MB) leprosy patients in the leprosy control program of the All Africa Leprosy and Rehabilitation Training Center in Ethiopia: appraisal of the recommended duration of MDT for MB patients.Int J Lepr Other Mycobact Dis. 1991 Dec;59(4):558-68. Int J Lepr Other Mycobact Dis. 1991. PMID: 1802938
-
Daily multidrug therapy for leprosy; results of a fourteen-year experience.Int J Lepr Other Mycobact Dis. 1997 Mar;65(1):37-44. Int J Lepr Other Mycobact Dis. 1997. PMID: 9207752 Clinical Trial.
-
Duration of multidrug therapy in paucibacillary leprosy patients; experience in the leprosy control program of the All Africa Leprosy and Rehabilitation Training Center (ALERT) in Ethiopia.Int J Lepr Other Mycobact Dis. 1992 Sep;60(3):436-44. Int J Lepr Other Mycobact Dis. 1992. PMID: 1474282 Review.
-
Clinical features and diagnosis of relapses in leprosy.Indian J Lepr. 1995 Jan-Mar;67(1):45-59. Indian J Lepr. 1995. PMID: 7622930 Review.
Cited by
-
Altered cytokine profiles in relapsed paucibacillary leprosy: a case report.BMC Infect Dis. 2021 Nov 13;21(1):1155. doi: 10.1186/s12879-021-06836-8. BMC Infect Dis. 2021. PMID: 34774006 Free PMC article.
-
Twelve months fixed duration WHO multidrug therapy for multibacillary leprosy: incidence of relapses in Agra field based cohort study.Indian J Med Res. 2013 Oct;138(4):536-40. Indian J Med Res. 2013. PMID: 24434261 Free PMC article. Clinical Trial.
-
The long-term impact of the Leprosy Post-Exposure Prophylaxis (LPEP) program on leprosy incidence: A modelling study.PLoS Negl Trop Dis. 2021 Mar 31;15(3):e0009279. doi: 10.1371/journal.pntd.0009279. eCollection 2021 Mar. PLoS Negl Trop Dis. 2021. PMID: 33788863 Free PMC article.
-
Leprosy--evolution of the path to eradication.Indian J Med Res. 2013 Jan;137(1):15-35. Indian J Med Res. 2013. Retraction in: Indian J Med Res. 2013 Dec;138(6):1038. PMID: 23481049 Free PMC article. Retracted.
-
Number of people requiring post-exposure prophylaxis to end leprosy: A modeling study.PLoS Negl Trop Dis. 2021 Feb 25;15(2):e0009146. doi: 10.1371/journal.pntd.0009146. eCollection 2021 Feb. PLoS Negl Trop Dis. 2021. PMID: 33630836 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Medical
Miscellaneous